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LETTERS TO THE EDITOR
Squamous Cell Carcinoma is not Associated with High Dermal
Mast Cell Prevalence in Humans
To the Editor:
Basal cell carcinomas (BCC) and squamous cell carcinomas
(SCC), commonly referred to as ‘‘nonmelanoma skin cancers’’,
are the most common form of cancers in Caucasian populations
(Armstrong and Kricker, 2001). Many genetic and environmental
factors contribute to the pathogenesis of these keratinocyte-
derived neoplasms, with exposure to ultraviolet radiation
(UVR) considered the major causal factor (Rosso et al, 1996;
English et al, 1998). Evidence from epidemiologic studies suggests
that the pattern of sun exposure and the dose of solar UVR
associated with the development of BCC di¡ers from that of
SCC. Intermittent intense sun exposure has been described
as one signi¢cant risk factor for BCC (Kricker et al, 1995;
Armstrong and Kricker, 2001), whereas the incidence of SCC
increases with age and cumulative sun exposure over a lifetime
(Strom and Yamamura, 1997; Armstrong and Kricker, 2001). The
process of keratinocyte transformation appears to be UVR
dose-dependent in these skin cancers. BCC are believed to arise
from mitotic epidermal cells rather than di¡erentiated epithelial
keratinocytes as for SCC and, therefore, may require less solar
UVR for malignant transformation to occur (Rosso et al, 1996).
UVR-induced cutaneous neoplasms are highly immunogenic
in that a competent immune response results in tumor rejection,
whereas impairment of the immune response by UVR enables
the progressive outgrowth of skin cancers (Kripke, 1981). Studies
in multiple murine strains have provided evidence of a functional
link between mast cell-derived histamine, dermal mast cell pre-
valence, and susceptibility to UVR-induced systemic immuno-
suppression (Hart et al, 1998). Recently, we reported that Danish
patients with a history of sporadic BCC (as the only skin cancer
type) have a higher dermal mast cell prevalence in nonsun-
exposed buttock skin than age- and sex-matched control subjects
(Grimbaldeston et al, 2000). Given that the patterns of sun expo-
sure in the epidemiology of the cancer di¡er between BCC and
SCC, in this study we evaluated dermal mast cell prevalence in
the buttock skin of Danish patients with SCC.
Twenty Danish patients with a history of histologically con-
¢rmed SCC and 20 sex- and age-matched control subjects parti-
cipated in the study (Table I). All volunteers were of Fitzpatrick
skin phototypes I, II, and III (Fitzpatrick, 1988). SCC patients
were recruited from the Department of Dermatology, Gentofte
Hospital (Hellerup, Denmark). Control subjects were selected on
the basis of no previous history of malignancy.The exclusion cri-
teria remained the same for this study as in a previous study of
BCC (only) patients (Grimbaldeston et al, 2000). In all the pa-
tients, SCC occurred at sun-exposed skin sites. The majority of
the patients (14 of 20) had a single SCC lesion and only one of
the 20 SCC patients presented with more than ¢ve SCC.The face
or scalp were the common sites of SCC localization (16 patients).
Three patients had lesions occur on the face together with either
the chest or the back. Two women and one man presented with
an SCC on the leg. Of the 20 patients, a subgroup of nine also
had BCC localized at sun-exposed skin sites with ¢ve of these
patients previously having at least 10 BCC each at the time of re-
cruitment. Though di¡ering in location and time of appearance,
BCC were localized at the same anatomic site as the SCC in ¢ve
of the nine patients. In this subgroup of nine patients, ¢ve people
reported that their ¢rst skin cancer was a BCC. Interestingly, all
¢ve patients had multiple BCC with three SCC patients present-
ing with greater than 10 BCC. Skin phototype showed no asso-
ciation with this phenomenon.
After informed consent, each participant had a 4mm punch
biopsy of buttock skin taken. All biopsies were coded in Den-
mark prior to being sent to Australia for quanti¢cation in a
blinded fashion of dermal mast cell prevalence. The code was re-
tained in Denmark and the SCC or control status for each biopsy
revealed only after analysis of the cohort had been completed.
Sections (4 mm) were cut, immunohistochemically stained with
an anti-histamine antibody (Chemicon,Temecula, CA), and der-
mal mast cell prevalence quanti¢ed using computer-generated
image analysis as previously described (Grimbaldeston et al,
2000). In brief, depending on the thickness of the dermis (papil-
lary þ reticular layer), 173^490 consecutive ¢xed ¢elds were cap-
tured in each section analyzed. Two consecutive sections from
each biopsy were assessed for dermal mast cell prevalence, and
the mean obtained. Fields were captured horizontally parallel to
the epidermis followed by the papillary and reticular layers of the
dermis using a  40 microscope objective and a  2.5 camera
eyepiece. Mast cells (as determined by histamine-staining cells)
per ¢xed ¢eld of 140 mm width were counted (but expressed per
mm2); the coe⁄cient of variation for measurement of mean der-
mal mast cell prevalence for 173^490 ¢elds waso15%. A study of
interbiopsy variability in dermal mast cell numbers from a single
donor (n¼ 6 buttock skin biopsies) over 6 mo demonstrated that
mast cell prevalence was reproducible over this period of time
(Grimbaldeston et al, 2000). Quanti¢cation of all biopsies was
performed by the same investigator.
In contrast to our previous ¢nding in Danish BCC patients
(Grimbaldeston et al, 2000), there was no signi¢cant di¡erence in
dermal mast cell prevalence between SCC patients and control
subjects (p¼ 0.978, Mann^Whitney U; Fig 1).
The fact that nine of our 20 Danish SCC patients also had a
history of BCC and mast cell prevalence equivalent to controls
(Fig 1) requires comment as we have established that patients
with BCC (only) had a signi¢cantly higher median dermal mast
cell density than controls.We propose that high dermal mast cell
prevalence in nonsun-exposed skin is only one susceptibility fac-
tor (assuming su⁄cient UVR) for the development of sporadic
BCC [nodular and super¢cial BCC types (Bastiaens et al, 1998)
could not be di¡erentiated due to removal by curettage]. BCC
patients with a lower dermal mast cell prevalence may have other
etiologic factors associated with the development of their BCC,
such as lesional mutations in the PTCH tumor suppressor gene
(Gailani et al, 1996). In sporadic BCC 30^40% have ‘‘UV signa-
ture’’ PTCH alterations (Lacour, 2002). To di¡erentiate further,
mutations in the PTCH tumor suppressor gene have been found
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in BCC lesions from patients with SCC and a history of multiple
sporadic BCC (Ping et al, 2001). Interestingly, ¢ve of the nine
Danish SCC patients had multiple (410) BCC and ¢ve of the
nine patients also reported that the ¢rst cutaneous cancer to ap-
pear was a BCC. Heterozygous PTCHþ /^ mice exposed to a
3minimal erythema dose of UV three times per week for 12 mo
all presented with multiple BCC after 3 mo of age followed by
the appearance of SCC 6 mo later (Aszterbaum et al, 1999). This
pattern of carcinogenesis resembles the clinical presentations of
the Danish SCC/BCC patients in our study.
The action spectrum, timing, and doses of UVR involved in
the development of SCC and BCC in humans are yet to be fully
elucidated but may di¡er between these keratinocyte-derived
cancers. Mechanisms modulating the immune response and
mutations in proto-oncogenes or suppressor genes may also vary
between subtype. We hypothesize that dermal mast cells may
function in humans, as in mice, by initiating immune suppres-
sion and when present at comparatively high prevalence, enabling
a permissive environment for the development of a subset of
BCC. In contrast, development of SCC and BCC in patients
with multiple SCC may be supported by additional immunomo-
dulatory mechanisms. UV-speci¢c cyclobutane pyrimidine di-
mers DNA lesions in the p53 gene have been found in over 90%
of SCC and in only 50% of BCC (Ananthaswamy et al, 1998).
Studies in murine strains suggest that cyclobutane pyrimidine di-
mers may play a part in UVR-induced immunomodulation
(Yarosh et al, 2000) by upregulation of tumor necrosis factor-a
gene transcription and protein expression (Kibitel et al, 1998), a
cytokine that has been linked with susceptibility to UVR-in-
duced local immunosuppression. Ultimately, identi¢cation of
the mechanism(s) that signal immune suppression may provide a
greater understanding of the etiology and pathogenesis of kerati-
nocyte-derived skin cancer that may present possibilities for in-
tervention and have implications for the development of
desirable sunscreen properties.
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